Gef gene therapy enhances the therapeutic efficacy of cytotoxics in colon cancer cells

Biomedicine and Pharmacotherapy

Volumn 66, Issue 7, 2012, Pages 563-567

  Ortiz, Raúl ^a   Prados, Jose ^b   Melguizo, Consolación ^b   Rama, Ana R ^a   Álvarez, Pablo J ^b   Rodríguez Serrano, Fernando ^b   Caba, Octavio ^a   Boulaiz, Houria ^b   Aranega, Antonia ^b  

^a UNIVERSITY OF JAÉN   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Apoptosis; Colon carcinoma; Combined therapy; Gef gene; Gene therapy

Indexed keywords

CYTOTOXIC AGENT; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CARCINOMA CELL; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; GEF GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SUICIDE GENE; SUICIDE GENE THERAPY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BACTERIAL TOXINS; CAMPTOTHECIN; CELL SURVIVAL; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; ESCHERICHIA COLI PROTEINS; FLUOROURACIL; GENETIC THERAPY; HUMANS; MEMBRANE PROTEINS; ORGANOPLATINUM COMPOUNDS;

EID: 84867331012     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.05.004     Document Type: Article

References (41)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Berrino F., De A.R., Sant M., Rosso S., Bielska-Lasota M., Coebergh J.W., et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-1999: results of the EUROCARE-4 study. Lancet Oncol 2007, 8:773-883.
3. Durai R., Yang S.Y., Seifalian A.M., Winslet M.C. Principles and applications of gene therapy in colon cancer. J Gastrointestin Liver Dis 2008, 17:59-67.
4. Millan A., Huerta S. Apoptosis-inducing factor and colon cancer. J Surg Res 2009, 151:163-170.
5. Prabhudesai S.G., Rekhraj S., Roberts G., Darzi A.W., Ziprin P. Apoptosis and chemo-resistance in colorectal cancer. J Surg Oncol 2007, 96:77-88.
6. Showalter S.L., Huang Y.H., Witkiewicz A., Costantino C.L., Yeo C.J., Green J.J., et al. Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells. Cancer Biol Ther 2008, 7:1584-1590.
7. Geden S.E., Gardner R.A., Fabbrini M.S., Ohashi M., Phanstiel I., Teter K. Lipopolyamine treatment increases the efficacy of intoxication with saporin and an anticancer saporin conjugate. Febs J 2007, 274:4825-4836.
8. Zhao J.M., Wen Z.J., Li Q., Wang Y., Wu H., Xu J., et al. A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus. Faseb J 2008, 22:4272-4280.
9. Brandtner E.M., Kodajova P., Hlavaty J., Jandl G., Tabotta W., Salmons B., et al. Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches. J Gene Med 2008, 10:113-122.
10. Poulsen T.T., Pedersen N., Poulsen H.S. Replacement and suicide gene therapy for targeted treatment of lung cancer. Clin Lung Cancer 2005, 6:227-236.
11. Boulaiz H., Prados J., Melguizo C., García A.M., Marchal J.A., Ramos J.L., et al. Inhibition of growth and induction of apoptosis in human breast cancer by transfection of gef gene. Br J Cancer 2003, 89:192-198.
12. Prados J., Melguizo C., Rama A.R., Ortiz R., Segura A., Boulaiz H., et al. Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells. Cancer Chemother Pharmacol 2010, 66:69-78.
13. Polyak K., Waldman T., He T.C., Kinzler K.W., Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 1996, 10:1945-1952.
14. Ganten T.M., Koschny R., Sykora J., Schulze-Bergkamen H., Büchler P., Haas T.L., et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 2006, 12:2640-2646.
15. Rama A.R., Prados J., Melguizo C., Ortiz R., Alvarez P.J., Rodríguez-Serrano F., et al. E phage gene transfection enhances sensitivity of lung and colon cancer cells to chemotherapeutic agents. Int J Oncol 2010, 37:1503-1514.
16. Kerr D.J., Seymour L.W., Maruta F. Gene therapy for colorectal cancer. Expert Opin Biol Ther 2003, 3:779-788.
17. Fillat C., Carrió M., Cascante A., Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther 2003, 3:13-26.
18. Lee S.W., Lee Y.L., Lee Y.J., Park S.Y., Kim I.S., Choi T.H., et al. Enhanced antitumor effects by combination gene therapy using MDR1 gene shRNA and HSV1-tk in a xenograft mouse model. Cancer Lett 2010, 291:83-89.
19. Wang Z.X., Bian H.B., Yang J.S., De W., Ji X.H. Adenovirus-mediated suicide gene therapy under the control of Cox-2 promoter for colorectal cancer. Cancer Biol Ther 2009, 8:1480-1488.
20. Teimoori-Toolabi L., Azadmanesh K., Amanzadeh A., Zeinali S. Selective suicide gene therapy of colon cancer exploiting the urokinase plasminogen activator receptor promoter. BioDrugs 2010, 24:131-146.
21. Zhang G., Liu T., Chen Y.H., Chen Y., Xu M., Peng J., et al. Tissue specific cytotoxicity of colon cancer cells mediated by nanoparticle-delivered suicide gene in vitro and in vivo. Clin Cancer Res 2009, 15:201-207.
22. Schepelmann S., Ogilvie L.M., Hedley D., Friedlos F., Martin J., Scanlon I., et al. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. Cancer Res 2007, 67:4949-4955.
23. Portsmouth D., Hlavaty J., Renner M. Suicide genes for cancer therapy. Mol Aspects Med 2007, 28:4-41.
24. Yang W.S., Park S.O., Yoon A.R., Yoo J.Y., Kim M.K., Yun C.O., et al. Suicide cancer gene therapy using pore-forming toxin, streptolysin O. Mol Cancer Ther 2006, 5:1610-1619.
25. Chen L.S., Wang M., Ou W.C., Fung C.Y., Chen P.L., Chang C.F., et al. Efficient gene transfer using the human JC virus-like particle that inhibits human colon adenocarcinoma growth in a nude mouse model. Gene Ther 2010, 17:1033-1041.
26. Yao Q., Cao S., Li C., Mengesha A., Low P., Kong B., et al. Turn a diarrhoea toxin into a receptor-mediated therapy for a plethora of CLDN-4-overexpressing cancers. Biochem Biophys Res Commun 2010, 398:413-419.
27. Agu C.A., Klei R., Schwab S., König-Schuster M., Kodajova P., Ausserlechner M., et al. The cytotoxic activity of the bacteriophage lambda-holin protein reduces tumour growth rates in mammary cancer cell xenograft models. J Gene Med 2006, 8:229-241.
28. Ortiz R., Prados J., Melguizo C., Rama A.R., Segura A., Rodríguez-Serrano F., et al. The cytotoxic activity of the phage E protein suppress the growth of murine B16 melanomas in vitro and in vivo. J Mol Med 2009, 87:899-911.
29. Rama A.R., Prados J., Melguizo C., Burgos M., Alvarez P.J., Rodriguez-Serrano F., et al. Synergistic antitumoral effect of combination E gene therapy and Doxorubicin in MCF-7 breast cancer cells. Biomed Pharmacother 2011, 65:260-270.
30. Boulaiz H., Prados J., Melguizo C., Marchal J.A., Carrillo E., Peran M., et al. Tumour malignancy loss and cell differentiation are associated with induction of gef gene in human melanoma cells. Br J Dermatol 2008, 159:370-378.
31. Prados J., Melguizo C., Rama A., Ortiz R., Boulaiz H., Rodriguez-Serrano F., et al. Combined therapy using suicide gef gene and Paclitaxel enhances growth inhibition of multicellular tumour spheroids of A-549 human lung cancer cells. Int J Oncol 2008, 33:121-127.
32. Prados J., Melguizo C., Ortiz R., Boulaiz H., Carrillo E., Segura A., et al. Regression of established subcutaneous B16-F10 murine melanoma tumors after gef gene therapy associated with the mitochondrial apoptotic pathway. Exp Dermatol 2010, 19:363-371.
33. Watanabe T., Komuro Y., Kiyomatsu T., Kanazawa T., Kazama Y., Tanaka J., et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res 2006, 66:3370-3374.
34. Kim H., Kokkotou E., Na X., Rhee S.H., Moyer M.P., Pothoulakis C., et al. Clostridium difficile Toxin A-induced colonocyte apoptosis involves p53-dependent p21(WAF1/CIP1) induction via p38 mitogen-activated protein kinase. Gastroenterology 2005, 129:1875-1888.
35. Faber C., Kirchner T., Hlubek F. The impact of microRNAs on colorectal cancer. Virchows Arch 2009, 454:359-367.
36. Yamakuchi M., Ferlito M., Lowenstein C.J. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008, 105:13421-13426.
37. Shieh G.S., Shiau A.L., Yo Y.T., Lin P.R., Chang C.C., Tzai T.S., et al. Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model. Cancer Res 2006, 66:9957-9966.
38. Deharvengt S., Rejiba S., Wack S., Aprahamian M., Hajri A. Efficient electrogene therapy for pancreatic adenocarcinoma treatment using the bacterial purine nucleoside phosphorylase suicide gene with fludarabine. Int J Oncol 2007, 30:1397-1406.
39. Hagiwara S., Kudo M., Nakatani T., Sakaguchi Y., Nagashima M., Fukuta N., et al. Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53. Br J Cancer 2007, 97:1532-1537.
40. Abaza M.S., Al-Saffar A., Al-Sawan S., Al-Attiyah R. c-myc antisense oligonucleotides sensitize human colorectal cancer cells to chemotherapeutic drugs. Tumour Biol 2008, 29:287-303.
41. Carrato A., Gallego-Plazas J., Guillén-Ponce C. Capecitabine plus oxaliplatin for the treatment of colorectal cancer. Expert Rev Anticancer Ther 2008, 8:161-174.